Ionis Pharmaceuticals Inc (NASDAQ: IONS) kicked off on Tuesday, down -3.53% from the previous trading day, before settling in for the closing price of $33.45. Over the past 52 weeks, IONS has traded in a range of $30.23-$52.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -5.56% over the past five years. While this was happening, its average annual earnings per share was recorded -26.21%. With a float of $154.59 million, this company’s outstanding shares have now reached $157.91 million.
Let’s look at the performance matrix of the company that is accounted for 1069 employees. In terms of profitability, gross margin is 96.82%, operating margin of -67.36%, and the pretax margin is -65.23%.
Ionis Pharmaceuticals Inc (IONS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ionis Pharmaceuticals Inc is 2.75%, while institutional ownership is 100.60%. The most recent insider transaction that took place on Mar 11 ’25, was worth 4,525. In this transaction Chief Executive Officer of this company sold 140 shares at a rate of $32.32, taking the stock ownership to the 180,980 shares. Before that another transaction happened on Mar 11 ’25, when Company’s Officer proposed sale 140 for $32.32, making the entire transaction worth $4,525.
Ionis Pharmaceuticals Inc (IONS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -26.21% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Take a look at Ionis Pharmaceuticals Inc’s (IONS) current performance indicators. Last quarter, stock had a quick ratio of 8.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.04, a number that is poised to hit -1.08 in the next quarter and is forecasted to reach -3.03 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Ionis Pharmaceuticals Inc (NASDAQ: IONS) saw its 5-day average volume 1.55 million, a negative change from its year-to-date volume of 1.65 million. As of the previous 9 days, the stock’s Stochastic %D was 35.67%. Additionally, its Average True Range was 1.38.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 19.71%, which indicates a significant decrease from 22.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.36% in the past 14 days, which was higher than the 40.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $32.68, while its 200-day Moving Average is $39.45. Nevertheless, the first resistance level for the watch stands at $33.42 in the near term. At $34.56, the stock is likely to face the second major resistance level. The third major resistance level sits at $35.37. If the price goes on to break the first support level at $31.47, it is likely to go to the next support level at $30.66. The third support level lies at $29.52 if the price breaches the second support level.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
The company with the Market Capitalisation of 5.13 billion has total of 158,965K Shares Outstanding. Its annual sales at the moment are 705,140 K in contrast with the sum of -453,900 K annual income. Company’s last quarter sales were recorded 226,580 K and last quarter income was -104,350 K.
